$ALLO
Allogene Therapeutics, Inc.

2020 Q1 Form 10-K Financial Statement

#000173728720000012 Filed on February 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.64M $15.21M $13.34M
YoY Change 19.75% 14.02%
% of Gross Profit
Research & Development $42.04M $49.76M $17.00M
YoY Change 79.64% 192.71%
% of Gross Profit
Depreciation & Amortization $1.893M $1.850M $550.0K
YoY Change 247.98% 236.36%
% of Gross Profit
Operating Expenses $57.68M $64.98M $30.34M
YoY Change 58.2% 114.17% 1516900.0%
Operating Profit -$57.68M -$64.58M -$33.05M
YoY Change 58.2% 95.41% 1652200.0%
Interest Expense $3.260M $3.660M $4.220M
YoY Change -32.51% -13.27%
% of Operating Profit
Other Income/Expense, Net $3.203M -$270.0K
YoY Change -33.62%
Pretax Income -$54.48M -$61.19M -$30.63M
YoY Change 72.21% 99.77% 1531400.0%
Income Tax $0.00 -$160.0K -$120.0K
% Of Pretax Income
Net Earnings -$54.48M -$61.03M -$30.51M
YoY Change 72.48% 100.04% 1525350.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$500.0K -$582.1K -$251.2K
COMMON SHARES
Basic Shares Outstanding 124.9M shares 121.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $492.9M $530.5M $459.4M
YoY Change 4.78% 15.49%
Cash & Equivalents $135.9M $175.1M $92.43M
Short-Term Investments $357.0M $355.4M $367.0M
Other Short-Term Assets $11.50M $11.60M $8.600M
YoY Change 9.52% 34.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $504.4M $544.6M $468.0M
YoY Change 5.83% 16.37%
LONG-TERM ASSETS
Property, Plant & Equipment $66.35M $56.45M $8.595M
YoY Change 224.83% 556.77%
Goodwill
YoY Change
Intangibles $0.00 $151.0K $754.0K
YoY Change -100.0% -79.97%
Long-Term Investments $65.00M $63.20M $262.0M
YoY Change -69.71% -75.88%
Other Assets $4.675M $4.618M $244.0K
YoY Change 982.18% 1792.62%
Total Long-Term Assets $184.1M $173.2M $305.9M
YoY Change -32.5% -43.37%
TOTAL ASSETS
Total Short-Term Assets $504.4M $544.6M $468.0M
Total Long-Term Assets $184.1M $173.2M $305.9M
Total Assets $688.5M $717.8M $773.9M
YoY Change -8.12% -7.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.199M $9.250M $12.34M
YoY Change -44.52% -25.03%
Accrued Expenses $19.60M $23.80M $17.10M
YoY Change 37.06% 39.18%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.82M $33.08M $29.46M
YoY Change -1.64% 12.29% 1472850.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.650M $4.351M $6.776M
YoY Change -39.82% -35.79%
Total Long-Term Liabilities $3.650M $4.351M $6.776M
YoY Change -39.82% -35.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.82M $33.08M $29.46M
Total Long-Term Liabilities $3.650M $4.351M $6.776M
Total Liabilities $82.00M $88.78M $70.69M
YoY Change 20.34% 25.59% 3534450.0%
SHAREHOLDERS EQUITY
Retained Earnings -$450.6M -$396.1M -$211.5M
YoY Change 85.35% 87.27% 919586.96%
Common Stock $1.056B $1.024B $914.4M
YoY Change 14.36% 11.99% 3516769.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $606.5M $629.0M $703.2M
YoY Change
Total Liabilities & Shareholders Equity $688.5M $717.8M $773.9M
YoY Change -8.12% -7.24%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2018 Q4
OPERATING ACTIVITIES
Net Income -$54.48M -$61.03M -$30.51M
YoY Change 72.48% 100.04% 1525350.0%
Depreciation, Depletion And Amortization $1.893M $1.850M $550.0K
YoY Change 247.98% 236.36%
Cash From Operating Activities -$40.81M -$50.27M -$21.48M
YoY Change 34.88% 134.03%
INVESTING ACTIVITIES
Capital Expenditures $12.25M -$14.11M -$1.320M
YoY Change 17.56% 968.94%
Acquisitions
YoY Change
Other Investing Activities -$2.750M $22.05M -$312.1M
YoY Change -106.35% -107.07%
Cash From Investing Activities -$15.01M $7.920M -$313.4M
YoY Change -145.63% -102.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $14.85M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $16.59M 56.47M 344.5M
YoY Change 2324.85% -83.61%
NET CHANGE
Cash From Operating Activities -$40.81M -50.27M -21.48M
Cash From Investing Activities -$15.01M 7.920M -313.4M
Cash From Financing Activities $16.59M 56.47M 344.5M
Net Change In Cash -$39.23M 14.12M 9.650M
YoY Change -1283.05% 46.32%
FREE CASH FLOW
Cash From Operating Activities -$40.81M -$50.27M -$21.48M
Capital Expenditures $12.25M -$14.11M -$1.320M
Free Cash Flow -$53.06M -$36.16M -$20.16M
YoY Change 30.44% 79.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001737287
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1905
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124267358 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121482671 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124267358 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121482671 shares
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1600000 USD
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-38693
CY2019 dei Entity Registrant Name
EntityRegistrantName
Allogene Therapeutics, Inc.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3562771
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
210 East Grand Avenue
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2019 dei City Area Code
CityAreaCode
650
CY2019 dei Local Phone Number
LocalPhoneNumber
457-2700
CY2019 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001 Per Share
CY2019 dei Trading Symbol
TradingSymbol
ALLO
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
1601000000 USD
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124906945 shares
CY2018Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
120200000 USD
CY2018Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
116800000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175126000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92432000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
355407000 USD
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
366952000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14043000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8598000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
544576000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
467982000 USD
CY2019Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
58322000 USD
CY2018Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
261966000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44495000 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33015000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56449000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8595000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
151000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
754000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4299000 USD
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1299000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4618000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
244000 USD
CY2019Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
4892000 USD
CY2018Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
0 USD
CY2019Q4 us-gaap Assets
Assets
717802000 USD
CY2018Q4 us-gaap Assets
Assets
773855000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9250000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12338000 USD
CY2019Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
23829000 USD
CY2018Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
17121000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33079000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29459000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51349000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34456000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4351000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6776000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
88779000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
70691000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
124000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
121000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1023876000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
914265000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396122000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211528000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1145000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
306000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
629023000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
703164000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
717802000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
773855000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
144535000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151860000 USD
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57473000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40982000 USD
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
202008000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
192842000 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
2000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-202008000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-192842000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2000 USD
CY2019 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
0 USD
CY2018 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
21211000 USD
CY2017Q4 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
0 USD
CY2019 us-gaap Interest Expense
InterestExpense
0 USD
CY2018 us-gaap Interest Expense
InterestExpense
3358000 USD
CY2017Q4 us-gaap Interest Expense
InterestExpense
0 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17351000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5789000 USD
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2019 us-gaap Other Expenses
OtherExpenses
268000 USD
CY2018 us-gaap Other Expenses
OtherExpenses
0 USD
CY2017Q4 us-gaap Other Expenses
OtherExpenses
0 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17083000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18780000 USD
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-184925000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-211622000 USD
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-331000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000 USD
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-184594000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-211505000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2000 USD
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
839000 USD
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
306000 USD
CY2017Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-183755000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-211199000 USD
CY2017Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2000 USD
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.31
CY2017Q4 allo Notes Receivable From Common Shareholders
NotesReceivableFromCommonShareholders
5000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2000 USD
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101061149 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28948386 shares
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26249993 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
0 USD
CY2017Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000 USD
CY2018 allo Stock Issued During Period Value Common Stock Issues
StockIssuedDuringPeriodValueCommonStockIssues
5000 USD
CY2018 allo Subscriptions Receivable From Preferred Stockholders
SubscriptionsReceivableFromPreferredStockholders
150000000 USD
CY2018 allo Stock Issued During Period Value Preferred Stock Issues
StockIssuedDuringPeriodValuePreferredStockIssues
150000000 USD
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2018 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
411052000 USD
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
141410000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
2000 USD
CY2019 allo Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
4590000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46063000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1783000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18566000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-211505000 USD
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
306000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
703164000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2959000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54219000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-184594000 USD
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
839000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
629023000 USD
CY2019 us-gaap Profit Loss
ProfitLoss
-184594000 USD
CY2018 us-gaap Profit Loss
ProfitLoss
-211505000 USD
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-2000 USD
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2017Q4 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
18566000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
603000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452000 USD
CY2017Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2018 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
109436000 USD
CY2017Q4 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
46063000 USD
CY2019 us-gaap Depreciation
Depreciation
4424000 USD
CY2018 us-gaap Depreciation
Depreciation
1048000 USD
CY2017Q4 us-gaap Depreciation
Depreciation
0 USD
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3596000 USD
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1036000 USD
CY2017Q4 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0 USD
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
6777000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1832000 USD
CY2017Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-331000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8598000 USD
CY2017Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 USD
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4374000 USD
CY2019 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
0 USD
CY2018 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
21211000 USD
CY2017Q4 allo Change In Fair Value Of Convertible Note Payable
ChangeInFairValueOfConvertibleNotePayable
0 USD
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3358000 USD
CY2017Q4 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 allo Income Loss From Cost Method Investment
IncomeLossFromCostMethodInvestment
-182000 USD
CY2018 allo Income Loss From Cost Method Investment
IncomeLossFromCostMethodInvestment
0 USD
CY2017Q4 allo Income Loss From Cost Method Investment
IncomeLossFromCostMethodInvestment
0 USD
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
CY2018 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
6000 USD
CY2017Q4 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5445000 USD
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
244000 USD
CY2017Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-985000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8800000 USD
CY2017Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6351000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12138000 USD
CY2017Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2000 USD
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2425000 USD
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 USD
CY2017Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-137350000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44653000 USD
CY2017Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50791000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3234000 USD
CY2017Q4 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 USD
CY2019 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0 USD
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
19235000 USD
CY2017Q4 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
0 USD
CY2017Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2019 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
5075000 USD
CY2018 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 USD
CY2018 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
2606000 USD
CY2017Q4 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0 USD
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
472578000 USD
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
252628000 USD
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
649307000 USD
CY2017Q4 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
CY2019 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
0 USD
CY2018 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
2098000 USD
CY2017Q4 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
0 USD
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
116842000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
164084000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-632798000 USD
CY2017Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
299281000 USD
CY2017Q4 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2017Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2019 allo Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions
0 USD
CY2018 allo Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions
11370000 USD
CY2017Q4 allo Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfStockOptions
0 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
54219000 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
343689000 USD
CY2017Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2958000 USD
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4668000 USD
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3182000 USD
CY2017Q4 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 USD
CY2017Q4 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 USD
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1783000 USD
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
CY2017Q4 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58960000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
771182000 USD
CY2017Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
85694000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
93731000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93731000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179425000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93731000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2018 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
411052000 USD
CY2017Q4 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
141410000 USD
CY2017Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2019 allo Convertible Preferred Stock Issued In Asset Acquisition
ConvertiblePreferredStockIssuedInAssetAcquisition
0 USD
CY2018 allo Convertible Preferred Stock Issued In Asset Acquisition
ConvertiblePreferredStockIssuedInAssetAcquisition
111770000 USD
CY2017Q4 allo Convertible Preferred Stock Issued In Asset Acquisition
ConvertiblePreferredStockIssuedInAssetAcquisition
0 USD
CY2019 allo Property Plant Equipment And Other Assets Acquired In Asset Acquisition
PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
0 USD
CY2018 allo Property Plant Equipment And Other Assets Acquired In Asset Acquisition
PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
111770000 USD
CY2017Q4 allo Property Plant Equipment And Other Assets Acquired In Asset Acquisition
PropertyPlantEquipmentAndOtherAssetsAcquiredInAssetAcquisition
0 USD
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13827000 USD
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
33015000 USD
CY2017Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
135000 USD
CY2018 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
356000 USD
CY2017Q4 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
CY2019 us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
3563000 USD
CY2018 us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
31000 USD
CY2017Q4 us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
0 USD
CY2019 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-4473000 USD
CY2018 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
0 USD
CY2017Q4 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
0 USD
CY2017Q4 allo Start Up Cost
StartUpCost
2000000 USD
CY2019Q4 allo Stock Issuance Maximum Value
StockIssuanceMaximumValue
250000000.0 USD
CY2019Q4 allo Stock Issuance Maximum Compensation Due To Third Party Percent
StockIssuanceMaximumCompensationDueToThirdPartyPercent
0.030
CY2019 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1965082 shares
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54200000 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1600000 USD
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3200000 USD
CY2019Q4 allo Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
500000 USD
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 USD
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 USD
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
588900000 USD
us-gaap Net Income Loss
NetIncomeLoss
-396100000 USD
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, the fair value of convertible notes payable upon conversion, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit and other Risks and Uncertainties</span></div><div style="text-indent:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of December 31, 2019 and 2018, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="text-indent:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</span></div>
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
200000 USD
CY2018 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0 USD
CY2018 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
109400000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
535042000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1595000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
713709000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
743000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
536629000 USD
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
122900000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
355407000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
58322000 USD
CY2019Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
536629000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
320000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
714132000 USD
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
85214000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
366952000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
261966000 USD
CY2018Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
714132000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
355407000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
375625000 USD
CY2019Q4 allo Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
58322000 USD
CY2018Q4 allo Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
240614000 USD
CY2019Q4 allo Available For Sale Securities Debt Maturities Within Three Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue
0 USD
CY2018Q4 allo Available For Sale Securities Debt Maturities Within Three Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearFairValue
36870000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
122900000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
61023000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
536629000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
714132000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2018Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P3Y
CY2019 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2018 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2019Q4 allo Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
6387000 USD
CY2018Q4 allo Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2356000 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2625000 USD
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2376000 USD
CY2019Q4 allo Accrued Interest On Short Term Marketable Securities
AccruedInterestOnShortTermMarketableSecurities
2403000 USD
CY2018Q4 allo Accrued Interest On Short Term Marketable Securities
AccruedInterestOnShortTermMarketableSecurities
3108000 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2628000 USD
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
758000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14043000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8598000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
61921000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9643000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5472000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1048000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56449000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8595000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4600000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000.0 USD
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
200000 USD
CY2018 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
612000 USD
CY2019Q4 allo Accrued Compensation And Related Benefits Current
AccruedCompensationAndRelatedBenefitsCurrent
9560000 USD
CY2018Q4 allo Accrued Compensation And Related Benefits Current
AccruedCompensationAndRelatedBenefitsCurrent
4111000 USD
CY2019Q4 allo Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4833000 USD
CY2018Q4 allo Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7808000 USD
CY2019Q4 allo Accrued Property And Equipment
AccruedPropertyAndEquipment
3575000 USD
CY2018Q4 allo Accrued Property And Equipment
AccruedPropertyAndEquipment
0 USD
CY2019Q4 allo Unvested Shares Liabilities Current
UnvestedSharesLiabilitiesCurrent
2843000 USD
CY2018Q4 allo Unvested Shares Liabilities Current
UnvestedSharesLiabilitiesCurrent
4590000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3018000 USD
CY2019Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
23829000 USD
CY2018Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
17121000 USD
CY2018Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
3258000 USD
CY2018Q2 allo Discount Rate For Valuation
DiscountRateForValuation
0.165
CY2018Q4 allo Operating Leases Number Of Lease Agreements
OperatingLeasesNumberOfLeaseAgreements
2 operatingLease
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5662000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7632000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7951000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8203000 USD
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1900000 USD
CY2019Q4 allo Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
63864000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
93312000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
35920000 USD
CY2019Q4 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
4367000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
53025000 USD
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
5900000 USD
CY2019 allo Shortterm Lease Rent Expense
ShorttermLeaseRentExpense
2400000 USD
CY2018 allo Shortterm Lease Rent Expense
ShorttermLeaseRentExpense
2600000 USD
CY2019Q4 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
0 USD
CY2018Q4 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
1600000 USD
CY2019 us-gaap Variable Lease Payment
VariableLeasePayment
1100000 USD
CY2019Q4 allo Operating Lease Asset Retirement Obligation
OperatingLeaseAssetRetirementObligation
400000 USD
CY2018Q4 allo Operating Lease Asset Retirement Obligation
OperatingLeaseAssetRetirementObligation
0 USD
CY2018Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
120200000 USD
CY2018Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
116800000 USD
CY2018Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
120200000 USD
CY2018Q4 us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.85
CY2018Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
141400000 USD
CY2019 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
0 USD
CY2018 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
21200000 USD
CY2018Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3400000 USD
CY2018Q2 allo Aggregate Purchase Price Shares Value
AggregatePurchasePriceSharesValue
300000000.0 USD
CY2018Q3 us-gaap Temporary Equity Shares Subscribed But Unissued Subscriptions Receivable
TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable
150000000.0 USD
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124267358 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124267358 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121482671 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121482671 shares
CY2019 allo Modification Of Convertible Preferred Stock For Common Stock
ModificationOfConvertiblePreferredStockForCommonStock
26249993 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
59500000 USD
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2018 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
110490000 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46063000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18566000 USD
CY2019Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2800000 USD
CY2018Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
4600000 USD
CY2019 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
900000 USD
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
400000 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017Q4 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000 USD
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000 USD
CY2017Q4 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000 USD
CY2017Q4 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-251000 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-89000 USD
CY2017Q4 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-81000 USD
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-30000 USD
CY2017Q4 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-332000 USD
CY2018 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-119000 USD
CY2017Q4 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-331000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000 USD
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-38834000 USD
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-44441000 USD
CY2017Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0 USD
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-12951000 USD
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-10652000 USD
CY2017Q4 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
0 USD
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2037000 USD
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3629000 USD
CY2017Q4 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0 USD
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1714000 USD
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
708000 USD
CY2017Q4 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2019 allo Income Tax Reconciliation Write Off Of In Process Research And Development
IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
0 USD
CY2018 allo Income Tax Reconciliation Write Off Of In Process Research And Development
IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
5247000 USD
CY2017Q4 allo Income Tax Reconciliation Write Off Of In Process Research And Development
IncomeTaxReconciliationWriteOffOfInProcessResearchAndDevelopment
0 USD
CY2018 allo Income Tax Reconciliation Change In Fair Value Of Convertible Notes
IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
4454000 USD
CY2017Q4 allo Income Tax Reconciliation Change In Fair Value Of Convertible Notes
IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
0 USD
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
49989000 USD
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
438000 USD
CY2017Q4 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0 USD
CY2019 allo Income Tax Reconciliation Change In Fair Value Of Convertible Notes
IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes
0 USD
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
41916000 USD
CY2017Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 USD
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1141000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-331000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-117000 USD
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
54018000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16437000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4239000 USD
CY2019Q4 allo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
14839000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1239000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
22770000 USD
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
23086000 USD
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2375000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
952000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
0 USD
CY2018Q4 allo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
9730000 USD
CY2017Q4 allo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6870000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
360000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2019Q4 allo Deferred Tax Liabilities Right Of Use Leased
DeferredTaxLiabilitiesRightOfUseLeased
12453000 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
105111000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51804000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
361000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
531000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0 USD
CY2018Q4 allo Deferred Tax Liabilities Right Of Use Leased
DeferredTaxLiabilitiesRightOfUseLeased
9239000 USD
CY2017Q4 allo Deferred Tax Liabilities Right Of Use Leased
DeferredTaxLiabilitiesRightOfUseLeased
0 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
393000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
118000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
0 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13207000 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9888000 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 USD
CY2019Q4 allo Deferred Tax Assets Net Of Deferred Tax Liabilities
DeferredTaxAssetsNetOfDeferredTaxLiabilities
91904000 USD
CY2018Q4 allo Deferred Tax Assets Net Of Deferred Tax Liabilities
DeferredTaxAssetsNetOfDeferredTaxLiabilities
41916000 USD
CY2017Q4 allo Deferred Tax Assets Net Of Deferred Tax Liabilities
DeferredTaxAssetsNetOfDeferredTaxLiabilities
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance Noncurrent
DeferredTaxAssetsValuationAllowanceNoncurrent
91904000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance Noncurrent
DeferredTaxAssetsValuationAllowanceNoncurrent
41916000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance Noncurrent
DeferredTaxAssetsValuationAllowanceNoncurrent
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
50000000.0 USD
CY2018 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
41900000 USD
CY2019 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
300000 USD
CY2018 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
100000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
920000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2228000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
920000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2018 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3148000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
920000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 USD
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-184594000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-211505000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2000 USD
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101061149 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28948386 shares
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26249993 shares
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.31
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27948931 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32087884 shares
CY2017Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36461000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45961000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55011000 USD
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-64575000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-31586000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-41243000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-50735000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-61030000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2597000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-135012000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22187000 USD
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-33046000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2597000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-134902000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-43497000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-30509000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-43.82
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.71
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37

Files In Submission

Name View Source Status
0001737287-20-000012-index-headers.html Edgar Link pending
0001737287-20-000012-index.html Edgar Link pending
0001737287-20-000012.txt Edgar Link pending
0001737287-20-000012-xbrl.zip Edgar Link pending
allo-20191231.htm Edgar Link pending
allo-20191231.xsd Edgar Link pending
allo-20191231xex1011.htm Edgar Link pending
allo-20191231xex1015.htm Edgar Link pending
allo-20191231xex231.htm Edgar Link pending
allo-20191231xex311.htm Edgar Link pending
allo-20191231xex312.htm Edgar Link pending
allo-20191231xex321.htm Edgar Link pending
allo-20191231xex322.htm Edgar Link pending
allo-20191231xex43.htm Edgar Link pending
allo-20191231_cal.xml Edgar Link unprocessable
allo-20191231_def.xml Edgar Link unprocessable
allo-20191231_g1.jpg Edgar Link pending
allo-20191231_g10.jpg Edgar Link pending
allo-20191231_g11.jpg Edgar Link pending
allo-20191231_g12.jpg Edgar Link pending
allo-20191231_g13.jpg Edgar Link pending
allo-20191231_g14.jpg Edgar Link pending
allo-20191231_g15.jpg Edgar Link pending
allo-20191231_g2.jpg Edgar Link pending
allo-20191231_g3.jpg Edgar Link pending
allo-20191231_g4.jpg Edgar Link pending
allo-20191231_g5.jpg Edgar Link pending
allo-20191231_g6.jpg Edgar Link pending
allo-20191231_g7.jpg Edgar Link pending
allo-20191231_g8.jpg Edgar Link pending
allo-20191231_g9.jpg Edgar Link pending
allo-20191231_htm.xml Edgar Link completed
allo-20191231_lab.xml Edgar Link unprocessable
allo-20191231_pre.xml Edgar Link unprocessable
allo-2019x1231xex107.htm Edgar Link pending
allogenelogo1.jpg Edgar Link pending
allogenelogo2.jpg Edgar Link pending
allogenelogo3.jpg Edgar Link pending
allogenelogo4.jpg Edgar Link pending
allogenelogo5.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image11.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending